Medifast, Inc.
MED · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $89 | $106 | $116 | $119 |
| % Growth | -15.3% | -8.8% | -2.8% | – |
| Cost of Goods Sold | $27 | $29 | $31 | $31 |
| Gross Profit | $62 | $77 | $84 | $88 |
| % Margin | 69.5% | 72.6% | 72.8% | 74.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $66 | $78 | $86 | $88 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $66 | $78 | $86 | $88 |
| Operating Income | -$4 | -$1 | -$1 | $1 |
| % Margin | -4.6% | -1% | -1.1% | 0.6% |
| Other Income/Exp. Net | $1 | $4 | $2 | $1 |
| Pre-Tax Income | -$3 | $3 | $1 | $1 |
| Tax Expense | -$0 | $0 | $1 | $0 |
| Net Income | -$2 | $2 | -$1 | $1 |
| % Margin | -2.5% | 2.3% | -0.7% | 0.7% |
| EPS | -0.21 | 0.23 | -0.07 | 0.07 |
| % Growth | -191.3% | 428.6% | -200% | – |
| EPS Diluted | -0.21 | 0.22 | -0.07 | 0.07 |
| Weighted Avg Shares Out | 11 | 11 | 11 | 11 |
| Weighted Avg Shares Out Dil | 11 | 11 | 11 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $4 | $3 | $3 |
| EBITDA | $1 | $3 | $2 | $4 |
| % Margin | 0.9% | 2.8% | 1.7% | 3.3% |